Symbiotec Pharmalab
01 Sep '26MAINBOARD
Min. Investment
₹14,070
Issue size
₹1757 Cr
GMP
Locked
Overall subscription: 0.78x
Expert verdict
IPO dates
24 Aug
Opening
27 Aug
Closing
28 Aug
Allotment
01 Sep
Listing
*Refunds will be initiated on 31 Aug '26
IPO quota
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| HNI (Min) | 14 | 210 | ₹2,07,480 |
Subscription (as on 24 August 2026, 05:30 PM)
Overall0.78x
Qualified institutional buyers
Non-Institutional Buyers
Retail Investors
Employee
About company
Founded: 2002|MD: Mr. Anil Satwani
- Symbiotec Pharmalab is a pharmaceutical and biotechnology company involved in the development and manufacturing of active pharmaceutical ingredients (APIs), biotechnology products, and complex injectables. Its operations span three platforms — organic chemistry, biotechnology, and complex injectables. The company has a portfolio of over 60 corticosteroid and steroid hormone APIs, including hydrocortisones, betamethasone, methylprednisolones, progesterones, estrogens, and testosterone. It also provides contract development and manufacturing organisation (CDMO) services to pharmaceutical and nutraceutical companies.
- As of March 31, 2026, the company had two operational API manufacturing facilities at Rau and Pithampur in Madhya Pradesh. It has also commissioned a biomanufacturing facility at Ujjain and a complex injectables facility at Mhow, Madhya Pradesh. The company operates three R&D centres in Indore focused on organic chemistry, biotechnology and complex injectables. Its products and services have been supplied to over 200 customers across more than 40 countries.
- Use of proceeds:
- The IPO consists of both a fresh issue and an offer for sale. Proceeds from the offer for sale segment will be directed to the respective selling shareholders, whereas the net proceeds from the fresh issue will be utilised for the following purposes:
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company — Rs 112.5 crore
- General corporate purposes
Issue Details & Objective
Lot size
15 Shares
Price band
₹938 to 988
Face value
₹2 per share
Financials
IPO reservation
Anchor investor - 29.94%
QIB - 19.96%
HNI - 14.97%
Retail - 34.93%
Employee - 0.19%
Download DRHP (IPO Doc)FAQs
Our SEBI-registered investment advisors give out verdicts for each IPO. You can refer to their expert verdict at the top of this page. Please note that these verdicts are for informational purposes only and should not be construed as investment advice. Markets are subject to risk, and investors should exercise their own discretion and diligence.
The issue size of Symbiotec Pharmalab IPO is ₹1757 Cr
The Symbiotec Pharmalab IPO will be open for applications from 24 Aug '26 to 27 Aug '26
The lot size of Symbiotec Pharmalab IPO is 15 Shares and its minimum investment amount is ₹14,070.
Grey market premium (GMP) is a premium amount at which grey market IPO shares are traded before they get listed in the stock exchange. The GMP for Symbiotec Pharmalab IPO is null
